EIKN

News

seekingalpha.comEikon Therapeutics: Initiating Coverage With A Cautious Buy Ratingseekingalpha.comJun 12

globenewswire.comEikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directorsglobenewswire.comJun 8

globenewswire.comEikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncologyglobenewswire.comMay 30

globenewswire.comEikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncologyglobenewswire.comMay 21

Trade EIKN

About Eikon Therapeutics, Inc. Common Stock

Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.

CEO: Roger Perlmutter
IPO Date: Feb 5, 2026

Market Data

Open: $9.80
High: $10.20
Low: $9.32
Volume: 205.7K
Avg Volume: 337.8K
52W High: $17.40
52W Low: $7.90

Valuation

Market Cap: $28M
Enterprise Value: $122M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-235M
Revenue: $0
Net Income: $-324M
Cash: $105M
Debt: $257M

Events

EarningsSep 2

EPS est. -1.558